Document is current
Any future updates will be listed below
-
Authors
Traini, Leonardo
Negueruela, Javier
Elvira, Bernat
St-Pierre-Wijckmans, Wadsen
Vandenbempt, Valerie
Buss, Carlos E.
Li, Ao
Pérez-Chávez, Israel
Ribeiro-Costa, Francisco
Nunes, Mariana
Messens, Joris
Ezeriņa, Daria
Hay, David C.
Bansal, Mayank
Gurzov, Esteban N. https://orcid.org/0000-0003-4642-0273
-
Funding
Funding for this research was provided by:
Juvenile Diabetes Research Foundation United States of America (2-SRA-2024-1566-S-B)
H2020 European Research Council (GA817940)
- License Information
-
More Information
Article History
Received: 30 December 2024
Accepted: 4 April 2025
First Online: 4 May 2025
Declarations
:
: Animal protocols underwent approval from the Commision d’Etique du Bien-Être Animal (CEBEA), Faculté de Médecine, Université libre de Bruxelles: dossier No 732N, title: PROTEIN TYROSINE PHOSPHATASES IN METABOLIC DISEASES: OXIDATION, DYSFUNCTION AND THERAPEUTIC POTENTIAL (METAPTPs), approved 27th March 2020, approved number ULB_IACUC-20–732; dossier No 802N, title: Breeding of NOD/SCID mice, approved 28th April 2022, approved number: AR 29052013. We obtained approved human ethics by the Comité d’Ethique hospitalo-facultaire Erasme Université libre de Bruxelles, title: Molecular mechanism of diabetes development, approved 5th December 2019, approved number P2019/498—PI Gurzov.
: David C. Hay is a founder, director and shareholder in Stimuliver ApS and Stemnovated Limited. We aim to further explore novel therapeutic avenues targeting TXNIP in metabolic disorders. Esteban N. Gurzov declares that there are no other relationships or activities that might bias, or be perceived to bias, the present work.
